PolyPeptide Group Future Growth
Future criteria checks 3/6
PolyPeptide Group is forecast to grow earnings and revenue by 0.07% and 11.5% per annum respectively. EPS is expected to grow by 103.7% per annum. Return on equity is forecast to be 9.8% in 3 years.
Key information
0.07%
Earnings growth rate
103.7%
EPS growth rate
Life Sciences earnings growth | 21.8% |
Revenue growth rate | 11.5% |
Future return on equity | 9.8% |
Analyst coverage | Low |
Last updated | 07 May 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 487 | 38 | -12 | 43 | 4 |
12/31/2025 | 411 | 15 | -13 | 49 | 5 |
12/31/2024 | 349 | -12 | -46 | 13 | 5 |
12/31/2023 | 320 | -51 | -20 | 36 | N/A |
9/30/2023 | 300 | -44 | -62 | 1 | N/A |
6/30/2023 | 279 | -37 | -104 | -35 | N/A |
3/31/2023 | 280 | -14 | -89 | -15 | N/A |
12/31/2022 | 281 | 8 | -73 | 5 | N/A |
9/30/2022 | 281 | 20 | -74 | 7 | N/A |
6/30/2022 | 281 | 33 | -75 | 9 | N/A |
3/31/2022 | 281 | 40 | -48 | 33 | N/A |
12/31/2021 | 282 | 47 | -20 | 57 | N/A |
9/30/2021 | 277 | 48 | -4 | 67 | N/A |
6/30/2021 | 271 | 48 | 13 | 77 | N/A |
3/31/2021 | 248 | 40 | 10 | 63 | N/A |
12/31/2020 | 224 | 31 | 6 | 49 | N/A |
12/31/2019 | 203 | 26 | 36 | 56 | N/A |
12/31/2018 | 181 | 24 | 5 | 23 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PPGNZ's forecast earnings growth (0.07% per year) is below the savings rate (1.8%).
Earnings vs Market: PPGNZ is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PPGNZ is expected to become profitable in the next 3 years.
Revenue vs Market: PPGNZ's revenue (11.5% per year) is forecast to grow faster than the UK market (3.7% per year).
High Growth Revenue: PPGNZ's revenue (11.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PPGNZ's Return on Equity is forecast to be low in 3 years time (9.8%).